Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.
about
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogueSkeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin ChemotherapyDefective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.Risk factors for anthracycline-associated cardiotoxicity.Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workersRecommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances.Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
P2860
Q28363755-0CCB189C-7686-4E41-A990-EDAEC495D3BEQ28548399-5C9BB670-25CE-4188-A36F-3FEC9DAE661BQ33232092-D81219A9-5097-4015-A08D-3A91FD8E7A6DQ33784640-D2017C0E-1C32-44E3-9C1C-2F27918CDD8EQ34186044-4D0D7176-4C56-4932-B93D-EA6D4AE9BC98Q34215077-7F581A4F-D024-444B-8755-DDC02E38FBDBQ34810063-0C1E8F7D-C56A-4052-B311-DBCBFF9CD85EQ36058273-61D5274D-E6C6-46E7-96CF-DF209353294AQ36921775-77EFB142-FAE7-4353-A838-2311F90EF4C4Q37631325-57D423A5-FC16-40EE-8DC4-1B3F2DC1A9CCQ38838517-A04A54B7-352E-4D34-9903-9894B7C394A5Q38913918-5F1ED886-234E-430D-A42C-05E7145B2F13Q39570922-377FF7B5-6C58-4B17-BE6F-63B6C19A3448Q42282655-E85E778F-9C43-4D2D-A1BF-40F5AADDE017Q44067892-42F8BA3E-608E-4F12-A28E-A281358AA88BQ44229618-08C264AB-FD4A-4D4C-BFAF-05F8BEB3857AQ46770269-4E8FB0EC-BF6B-4C48-B07A-5DA8252E6B17Q47327199-77829D1B-2245-4FFF-97A7-8A91EF2B90D8Q48231823-1F55778E-74C2-46CE-AFE7-4533649DF0B5Q53672562-93B17A08-3EC5-4E94-9E5B-A60D58768FAB
P2860
Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Time-related increases in card ...... ocardial contractile function.
@ast
Time-related increases in card ...... ocardial contractile function.
@en
type
label
Time-related increases in card ...... ocardial contractile function.
@ast
Time-related increases in card ...... ocardial contractile function.
@en
prefLabel
Time-related increases in card ...... ocardial contractile function.
@ast
Time-related increases in card ...... ocardial contractile function.
@en
P2093
P2860
P1476
Time-related increases in card ...... ocardial contractile function.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1993.TB13909.X
P407
P577
1993-11-01T00:00:00Z